147 completed, 82 terminated, 38 recruiting, 37 active not recruiting. 186 Phase 2, 157 Phase 1, 25 Not applicable, 12 Phase 3, 7 Phase 4.
Follow Metastatic Melanoma: new trials by email Literature Review of Metastatic Melanoma trials Research Report on Metastatic Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma iSCIB1+, Nivolumab & Ipilimumab, Placebo - Melanoma (Skin Cancer), Advanced Melanoma | Phase 3 | Not yet recruiting | Scancell Ltd | 550 | 2026-12-01 | 2026-09-11 |
| CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery to Improve Treatment of Melanoma Brain Metastases Emavusertib, Pembrolizumab, Stereotactic Radiosurgery - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 1 / Phase 2 | Suspended | Mayo Clinic | 23 | 2026-11-30 | 2026-10-20 |
| A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India Nivolumab + Relatlimab - Unresectable Melanoma, Metastatic Melanoma | Phase 4 | Not yet recruiting | Bristol-Myers Squibb | 40 | 2026-11-15 | 2026-08-12 |
| Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer Biospecimen Collection, Cholecalciferol, Computed Tomography - Advanced Hepatocellular Carcinoma, Advanced Melanoma | Phase 2 | Not yet recruiting | University of Southern California | 46 | 2026-11-01 | 2026-09-23 |
| Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis Nivolumab and Relatlimab, Melphalan - Metastatic Melanoma, Liver Metastases | Phase 1 / Phase 2 | Recruiting | University of Wisconsin, Madison | 15 | 2026-10-01 | 2026-09-29 |
| Markers of Efficacy to Immunotherapy in Patients With Metastatic Melanoma Metastatic Melanoma | Not yet recruiting | European Institute of Oncology | 200 | 2026-08-27 | 2026-08-31 | |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab Nivolumab, Relatlimab, Ipilimumab - Metastatic Melanoma, Advanced Melanoma | Phase 2 | Recruiting | NYU Langone Health | 90 | 2026-04-13 | 2026-08-24 |
| IL-17 Blockade to Decrease irAEs (REPLAY) Secukinumab Injection - Metastatic Melanoma | Phase 1 | Recruiting | Duke University | 4 | 2026-03-12 | 2026-06-04 |
| A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 Observational study with no interventions - Melanoma, Metastatic Melanoma | Recruiting | Replimune, Inc. | 50 | 2025-12-12 | 2026-01-12 | |
| STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma Aldesleukin, Biopsy, Biospecimen Collection - Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma | Phase 1 | Withdrawn | City of Hope Medical Center | 2025-12-05 | 2025-12-24 | |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma Lifileucel - Melanoma (Skin Cancer), Unresectable Melanoma | Phase 2 | Active not recruiting | Iovance Biotherapeutics, Inc. | 24 | 2025-11-28 | 2026-10-01 |
| Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma 30 Minutes Cycle Ergometer - Metastatic Melanoma | Not applicable | Recruiting | Universitätsklinikum Hamburg-Eppendorf | 40 | 2025-11-14 | 2026-05-04 |
| A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing Atezolizumab - Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2025-11-04 | 2026-10-16 |
| NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis NovoTTF-200A, Pembrolizumab - Metastatic Melanoma, Melanoma Brain Metastasis | Phase 1 / Phase 2 | Withdrawn | Brown University | 2025-10-30 | 2026-01-02 | |
| Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung Aerosol Sargramostim, Biospecimen Collection, Computed Tomography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Lung | Phase 1 | Withdrawn | Mayo Clinic | 2025-10-28 | 2025-08-07 | |
| Mirdametinib in Patients With Advanced NF1-mutant Melanoma Mirdametinib - Advanced Unresectable Melanoma, Metastatic Melanoma | Phase 2 | Recruiting | Kevin Kim, MD | 10 | 2025-10-13 | 2025-11-19 |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma Adze1.C - Metastatic Melanoma | Phase 1 | Recruiting | Adze Biotechnology Australia Pty Ltd | 30 | 2025-10-01 | 2026-07-08 |
| Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma Stereotactic Body Radiation Therapy (SBRT) - Metastatic Melanoma, OligoProgressive Metastatic Disease | Not applicable | Recruiting | University Health Network, Toronto | 52 | 2025-07-24 | 2026-03-05 |
Showing 20 of 362. Sign in to see all of them.
Melanoma (362) · Neoplasm Metastasis (55) · Carcinoma, Non-Small-Cell Lung (33) · Skin Neoplasms (28) · Brain Neoplasms (27) · Carcinoma, Renal Cell (27) · Lung Neoplasms (22) · Neoplasms (18) · Breast Neoplasms (14) · Uveal Melanoma (14) · Squamous Cell Carcinoma of Head and Neck (13) · Carcinoma, Hepatocellular (10) · Carcinoma, Transitional Cell (7) · Colorectal Neoplasms (7) · Kidney Neoplasms (7)
Neoplasms by Histologic Type (362) · Neoplasms by Site (362) · Neoplasms, Germ Cell and Embryonal (362) · Neoplasms, Nerve Tissue (362) · Neuroectodermal Tumors (362) · Nevi and Melanomas (362) · Skin Diseases (362) · Skin and Connective Tissue Diseases (362) · Neuroendocrine Tumors (361) · Neoplasms (344) · Skin Neoplasms (334) · Pathological Conditions, Signs and Symptoms (58) · Pathologic Processes (57) · Neoplastic Processes (56) · Neoplasms, Glandular and Epithelial (53)
Nivolumab (60) · Ipilimumab (57) · pembrolizumab (50) · Cyclophosphamide (42) · aldesleukin (36) · Interleukin-2 (28) · fludarabine (26) · Magnetic Resonance Spectroscopy (21) · Specimen Handling (21) · fludarabine phosphate (21) · CTLA-4 Antigen (18) · Biopsy (16) · Radiosurgery (16) · Temozolomide (14) · dabrafenib (13)
National Cancer Institute (NCI) (40) · M.D. Anderson Cancer Center (26) · Mayo Clinic (11) · Iovance Biotherapeutics, Inc. (7) · H. Lee Moffitt Cancer Center and Research Institute (6) · Bristol-Myers Squibb (5) · Hoffmann-La Roche (5) · Providence Health & Services (5) · University of Southern California (5) · California Pacific Medical Center Research Institute (4) · Institute of Oncology Ljubljana (4) · Ludwig Institute for Cancer Research (4) · Memorial Sloan Kettering Cancer Center (4) · Novartis Pharmaceuticals (4) · Pierre Fabre Medicament (4)
United States (257) · France (34) · Spain (22) · Germany (20) · Australia (19) · United Kingdom (18) · Italy (17) · Canada (15) · Switzerland (12) · Belgium (10) · Israel (10) · Netherlands (10) · Denmark (9) · Poland (6) · Sweden (6)
Steven A Rosenberg, M.D. (14) · Amod Sarnaik, M.D. (3) · Rodabe N Amaria (3) · Anna Pavlick, DO (2) · Antoni Ribas, MD (2) · Antoni Ribas, MD, PhD (2) · Brendan D Curti, MD (2) · Brendan D. Curti, MD (2)
PMID 25432172, PMID 32747469, PMID 38939518, PMID 39462179, PMID 39504507, PMID 11869699, PMID 12569285, PMID 15944250, PMID 16882708, PMID 17203752, PMID 19454513, PMID 19538053, PMID 20406835, PMID 20564157, PMID 22028492, PMID 22056381, PMID 22261812, PMID 22555974, PMID 22658127, PMID 22719881, PMID 22864522, PMID 22932225, PMID 23377668, PMID 23519018, PMID 23676418, PMID 23728176, PMID 23861247, PMID 23934126, PMID 23969699, PMID 24590637, PMID 25062770, PMID 25369488, PMID 25695689, PMID 25891304, PMID 26202595, PMID 27166673, PMID 27622997, PMID 28428882, PMID 28428884, PMID 28489678, PMID 28497258, PMID 28810925, PMID 28915798, PMID 29254506, PMID 29306769, PMID 29470191, PMID 29510745, PMID 29552014, PMID 29784747, PMID 29899062
2018 (5), UM1CA186709 (5), P30CA014089 (4), U01CA062490 (4), 2019 (3), U10CA180888 (3), UM1CA186691 (3), UM1CA186704 (3), P30CA006516 (2), P30CA015083 (2), P30CA015704 (2), P30CA016672 (2), P30CA033572 (2), P30CA072720 (2), P30CA138292 (2)